ClarVista develops the HARMONI Modular IOL System, a novel intraocular lens (IOL) used to restore vision and improve patient outcomes after cataract surgery, the highest volume outpatient procedure.
The Series B financing permit the Company to advance the clinical development of HARMONI Modular IOL capable of optimizing vision after cataract surgery. Alcon, who also participated in the financing, acquired ClarVista Medical in 2017. Although terms were not publicly disclosed this outcome represented an ultimate exit and successful transaction for investors.
If you would like to learn more information about this transaction contact us below.